155 related articles for article (PubMed ID: 16086880)
1. [Selecting postoperative chemotherapy regimen and optimizing therapy cycle for stage II-IV ovarian epithelial carcinoma].
Huang YW; Li YJ; Li MD
Ai Zheng; 2005 Aug; 24(8):994-7. PubMed ID: 16086880
[TBL] [Abstract][Full Text] [Related]
2. [Clinical characteristics and prognosis of epithelial ovarian cancer in young women].
Tang L; Zheng M; Xiong Y; Ding H; Liu FY
Ai Zheng; 2008 Sep; 27(9):951-5. PubMed ID: 18799034
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
Gao KF; Liu FY; Chen FJ; Feng YL
Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
[TBL] [Abstract][Full Text] [Related]
4. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].
Yuan GW; Wu LY; Yao HW; Hou JL; Li XG; Liu LY
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):710-3. PubMed ID: 20021871
[TBL] [Abstract][Full Text] [Related]
6. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
7. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
Zhao XD; Zhang Y; He SR; Yang L
Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810
[TBL] [Abstract][Full Text] [Related]
8. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
9. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
[TBL] [Abstract][Full Text] [Related]
10. A comparative study on hematological effects of carboplatin plus cyclophosphamide and carboplatin plus paclitaxel chemotherapy for the first line treatment of epithelial ovarian cancer.
Vapattanawong P
J Med Assoc Thai; 2006 Sep; 89(9):1357-61. PubMed ID: 17100369
[TBL] [Abstract][Full Text] [Related]
11. [Treatment and prognostic factors of epithelial ovarian cancer].
Wei L; Qian H; Li W
Zhonghua Fu Chan Ke Za Zhi; 1997 Aug; 32(8):476-9. PubMed ID: 9639741
[TBL] [Abstract][Full Text] [Related]
12. [Clinical and pathological features of borderline ovarian tumors].
Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693
[TBL] [Abstract][Full Text] [Related]
13. A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer.
Mouratidou D; Gennatas C; Michalaki V; Papadimitriou A; Andreadis CH; Sykiotis C; Tsavaris N
Anticancer Res; 2007; 27(1B):681-5. PubMed ID: 17348460
[TBL] [Abstract][Full Text] [Related]
14. Comparative study on three chemotherapeutic regimens for the treatment of advanced epithelial ovarian cancer.
Wang C; Gu M; Wang S; Ma D
J Tongji Med Univ; 2000; 20(4):343-4. PubMed ID: 12840932
[TBL] [Abstract][Full Text] [Related]
15. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic value of serum CA(125) level change during chemotherapy post-surgery in patients with advanced epithelial ovarian carcinoma].
Lan CY; Huang H; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):732-6. PubMed ID: 19087537
[TBL] [Abstract][Full Text] [Related]
17. Chronic administration of single weekly paclitaxel in heavily pretreated ovarian cancer patients.
Yamamoto K; Oogi S; Inoue H; Kudoh K; Kita T; Kikuchi Y
Curr Med Chem; 2004 Feb; 11(4):425-8. PubMed ID: 14965223
[TBL] [Abstract][Full Text] [Related]
18. Prognostic results of cisplatin IP and carboplatin IV with G-CSF in patients with ovarian cancer.
Adachi S; Itani Y; Ito K; Noda T; Shintani M; Saito K; Furukawa N; Tomii Y
Oncol Rep; 2001; 8(1):27-31. PubMed ID: 11115564
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study.
Altman AD; McGee J; May T; Lane K; Lu L; Xu W; Ghatage P; Rosen B
Gynecol Oncol; 2017 Nov; 147(2):257-261. PubMed ID: 28800940
[TBL] [Abstract][Full Text] [Related]
20. [Cytoreductive surgery plus combined chemotherapy for the treatment of advanced ovarian cancer].
Li M; Huang X
Zhonghua Fu Chan Ke Za Zhi; 1996 Oct; 31(10):621-3. PubMed ID: 9275460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
